retatrutide phase 2 trial new england journal of medicine approval: FDA status, clinical results, and when it could be available Retatrutide, a GIP, GLP-1 and

AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication

L., Murphy, K

Recurring burps with a rotten egg smell, on the other hand, may come from something more serious

This eliminates surprise charges and makes budgeting for treatment straightforward

A major real-world study published in early 2026 led by researchers at Johns Hopkins Bloomberg School of Public Health and analysing electronic health records from approximately 175,000 people with T1D in the US found that those taking GLP-1 drugs had a roughly 15% lower five-year risk of major cardiovascular events and a 19% lower risk of end-stage kidney disease, without any increase in hospitalisation for DKA or severe hypoglycemia

14 Le says these challenges raise health equity questions